相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)
J. Chandra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity
Dayson Moreira et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha B. Nagarsheth et al.
NATURE MEDICINE (2021)
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
Samuel T. Pellom et al.
JCI INSIGHT (2021)
De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers-HPV and Beyond
Alexander Ruehle et al.
CANCERS (2021)
Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).
Charalampos S. Floudas et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
Ajaz A. Bhat et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo et al.
IMMUNITY (2020)
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
Petr Szturz et al.
ORAL ONCOLOGY (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
Steven F. Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
Cornelis J. M. Melief et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Aaron R. Lim et al.
ELIFE (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Comprehensive analysis of significant genes and immune cell infiltration in HPV-related head and neck squamous cell carcinoma
Lei Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Kathryn M. Cappell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
Jin Won Youn et al.
LANCET ONCOLOGY (2020)
Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis
Mia Petljak et al.
CELL (2019)
Infiltration of FoxP3+Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma
Imelda Seminerio et al.
CANCERS (2019)
Neutrophils infiltration and its correlation with human papillomavirus status in the oral squamous cell carcinoma
Chen Li et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Self-Assembled Nanofibers Elicit Potent HPVI6 E7-Specific Cellular Immunity And Abolish Established TC-I Graft Tumor
Sijin Li et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
APhase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers
Sanja Stevanovic et al.
CLINICAL CANCER RESEARCH (2019)
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Hisham Mehanna et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2019)
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Masao Hashimoto et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
Partha Basu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis
Xiaohang Chen et al.
MOLECULAR IMMUNOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
Maura L. Gillison et al.
ONCOLOGIST (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort
Mathew Geltzeiler et al.
ORAL ONCOLOGY (2018)
Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project
Pernille Lassen et al.
RADIOTHERAPY AND ONCOLOGY (2018)
High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus
Imelda Seminerio et al.
Oncotarget (2018)
Treatment-naive HPV plus head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
Steven F. Gameiro et al.
ONCOIMMUNOLOGY (2018)
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
Smita S. Chandran et al.
LANCET ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma
Nadege Kindt et al.
ORAL ONCOLOGY (2017)
LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma
Xiangrui Ma et al.
ONCOTARGET (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
CD8+tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)
Panagiotis Balermpas et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus-associated cancers
Miriam Reuschenbach et al.
CANCER (2016)
A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency
Simone Punt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Elham Beyranvand Nejad et al.
CANCER RESEARCH (2016)
Current state in the development of candidate therapeutic HPV vaccines
Andrew Yang et al.
EXPERT REVIEW OF VACCINES (2016)
Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx
Ankur Chakravarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Lindsey M. Draper et al.
CLINICAL CANCER RESEARCH (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
Simona Partlova et al.
ONCOIMMUNOLOGY (2015)
A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Dan P. Zandberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer
Falguni Parikh et al.
CANCER RESEARCH (2014)
Epidemiology of HPV-associated oropharyngeal cancer
Kristen B. Pytynia et al.
ORAL ONCOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor associated macrophages and neutrophils in cancer
Maria Rosaria Galdiero et al.
IMMUNOBIOLOGY (2013)
Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma
Nadia Lago Costa et al.
ORAL ONCOLOGY (2013)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
Jean-Luc Brun et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2011)
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Alyssa D. Gregory et al.
CANCER RESEARCH (2011)
Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma
Dalal Al-Qahtani et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2011)
Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients
Yu-jie Liang et al.
ORAL ONCOLOGY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oropharyngeal Cancer Epidemic and Human Papillomavirus
Torbjorn Ramqvist et al.
EMERGING INFECTIOUS DISEASES (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Human Dendritic Cells Produce TGF-β1 under the Influence of Lung Carcinoma Cells and Prime the Differentiation of CD4+CD25+Foxp3+ Regulatory T Cells
Ingrid E. Dumitriu et al.
JOURNAL OF IMMUNOLOGY (2009)
Human leukocyte antigen-G and cancer immunoediting
Mirjana Urosevic et al.
CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Carole Fakhry et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells
Fabian Benencia et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial
Alessandro D. Santin et al.
JOURNAL OF VIROLOGY (2008)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
PC Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
Human papillomavirus type 16 and TP53 mutation in oral cancer:: Matched analysis of the IARC multicenter study
M Dai et al.
CANCER RESEARCH (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
分享论文
